Small molecule modulators of cyclin-dependent kinases for cancer therapy.
about
A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapyCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsE2F-3B is a physiological target of cyclin AExpression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity.Probing the probes: fitness factors for small molecule tools.Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer.Derangement of growth and differentiation control in oncogenesis.Selectivity and potency of cyclin-dependent kinase inhibitors.Defects in G1-S cell cycle control in head and neck cancer: a review.Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitorsPharmacogenetic candidate genes for melanoma.Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapyMulti-algorithm and multi-model based drug target prediction and web server.Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer.Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.Molecular targeted agents for gastric and gastroesophageal junction cancer.Repression of IRF-4 target genes in human T cell leukemia virus-1 infection.Targeting the ATR-CHK1 Axis in Cancer TherapyChk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects.Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors.Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor.The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.Variation in expression and protein localization of the PIN family of auxin efflux facilitator proteins in flavonoid mutants with altered auxin transport in Arabidopsis thaliana.The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
P2860
Q24538802-14F6E4F2-A1EB-4FAD-AD16-1E53D646E1DDQ28540339-C7E01FFC-5F14-4447-98AF-6AA1E76FE3F8Q28592030-D494CC6D-20C8-44EF-B727-AAC195753FC2Q33311729-D7DC5C0F-F538-4101-850C-7BC956CB033CQ34001269-52B68E4A-3AA4-4B46-A421-75036CEE680DQ34094154-76A7BC44-0188-46AD-A219-5C7EFA69CE1BQ34189632-1C5A53DC-F6A8-41BC-8FA4-CC36BD209242Q34488147-89F53153-D88B-4AAB-9C77-71C8B6DF8DBAQ34651981-B6784451-51FC-4866-B6ED-8E46E8FD5F30Q34733424-598C1D9A-8A26-4830-9AE7-AFB288C33A3EQ35542088-F697B401-FD5D-4505-A892-FD64B5010C10Q35574952-08A9B7C8-AF89-4803-A2A5-E5FBA613D7D1Q35747628-8B4E4A1A-7960-4FA4-9735-969CA150CD50Q36015334-CAA79B2B-EBCF-460D-89A4-9BCD8400E91CQ36287437-3D46AE9F-3031-44D0-8737-AAD5586A348EQ36496793-9CA4C9C7-A39F-4FB5-B969-F761C2BAEB94Q37707406-8B50296F-1159-42FF-A2E9-F2EE24BAEF24Q37962816-BE5D71DE-DF6A-4CA5-A51A-AB3FA1520ED4Q38362324-E08A3227-5AFC-4ABF-A552-E96A319B35C5Q38817102-73131A32-B427-4FDC-BF42-F887900A90F5Q39698998-DB31F2A9-48AF-4F10-9248-C691C4A79FDEQ40765650-79EB65BB-A558-4168-A205-79ADF6AA322CQ43966314-27BDE313-1F35-477F-A4D2-04EA4E03C1E3Q44678684-4141B608-62B4-49D4-A3AF-92EF836BC093Q45947436-73658463-4F9F-45DA-8EF1-80ECEE970B8BQ47315807-C7A63880-481F-4D3F-B515-CED1C83D658DQ48575949-F133BFF6-B208-4CE1-98E7-7A66526A6678Q50102285-F99AC691-7B1B-41AF-AA3F-4D4A33A5BB6BQ53594161-274E0A2B-4326-40E5-89DE-EBACE1EB148B
P2860
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@ast
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@en
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@nl
type
label
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@ast
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@en
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@nl
prefLabel
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@ast
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@en
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@nl
P2860
P356
P1433
P1476
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
@en
P2093
A M Senderowicz
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204085
P407
P577
2000-12-01T00:00:00Z
P5875
P6179
1010692378